Researchers reporting August 26 in the Cell Press journal Cell Biomaterials have used engineered nanoparticles to grow new neurons in human brain organoids and, in mice, to rebuild neural circuits and improve cognitive performance. That matters because the adult human brain has very little ability to replace neurons lost to Alzheimer's disease, and the drugs available now can slow decline without reversing it.
The system, called Nano-ERASER, is a polymer nanogel that carries antibodies designed to degrade a specific target protein. It crosses the blood-brain barrier and enters astrocytes, the star-shaped support cells that are plentiful throughout the central nervous system. Once inside, the antibodies break down a protein called PTBP1, and the loss of that protein prompts the astrocytes to convert into neurons. According to Xu, whose team developed the approach, the new neurons matured and survived, and treated mice showed considerably higher neuron density in the brain.
One point of contrast the researchers draw is with gene-editing approaches such as CRISPR. Nano-ERASER does not alter DNA, and the cell reprogramming it triggers is reversible - a design choice that could make the effect easier to control or halt than a permanent genetic change.
This is early-stage work in organoids and mice, not people, and the leap from a mouse cognitive test to meaningful benefit in patients with Alzheimer's is a long one. Still, the idea of coaxing the brain's own support cells into replacing lost neurons, without editing the genome, gives researchers a repair strategy to pursue alongside the amyloid- and tau-focused drugs that dominate the field.